Aquestive Therapeutics (AQST) Receivables - Other (2017 - 2026)

Aquestive Therapeutics' Receivables - Other history runs 10 years deep, the most recent figure standing at $1.6 million for Q1 2026.

• On a quarterly basis, Receivables - Other fell 27.47% year-over-year to $1.6 million in Q1 2026; TTM through Mar 2026 was $1.6 million, a 27.47% decrease from a year earlier, with the FY2025 full-year figure at $9.8 million, up 294.26% from the prior year.
• Receivables - Other fell to $1.6 million in Q1 2026 per AQST's latest filing, from $9.8 million in the prior quarter.
• Across five years, Receivables - Other topped out at $9.8 million in Q4 2025 and bottomed at $1.6 million in Q1 2026.
• The 5-year median for Receivables - Other is $2.2 million (2023), against an average of $2.7 million.
• Across the five-year window, Receivables - Other plunged 53.38% in 2024 and soared 294.26% in 2025, its largest moves.
• Year by year, Receivables - Other stood at $2.1 million in 2022, then surged by 36.28% to $2.9 million in 2023, then declined by 15.16% to $2.5 million in 2024, then surged by 294.26% to $9.8 million in 2025, then slumped by 83.54% to $1.6 million in 2026.
• Per Business Quant, the three latest AQST Receivables - Other figures stand at $1.6 million (Q1 2026), $9.8 million (Q4 2025), and $2.3 million (Q3 2025).